Participate in NHLBI Clinical Trials

NHLBI sponsors or supports many trials that may be relevant to LAM. See if you or someone you know is eligible to participate in our clinical trials described below. Also visit our LAM research studies page for more information about our LAM clinical trials.

Are you 16 or older with LAM and interested in helping LAM research?

This study is trying to understand the genes and proteins that are responsible for causing lung damage in patients with LAM. You must be 16 years or older and have LAM or TSC-LAM. Visit Study of the Disease Process of Lymphangioleiomyomatosis for more information and to learn how to participate in this study.

Are you an adult with advanced lung disease?

This study will examine how adults with advanced lung disease respond to the way six-minute walk tests are administered and whether behavior and different instructions influence test results. Visit The Six Minute Walk Test: Influence of Patient Effort on Results and Interpretation (fast vs far) for more information and to learn how to participate in this study.

Are you an adult woman with LAM interested in sirolimus or everolimus treatment?

This study is trying to optimize sirolimus or everolimus treatment to prevent progression to more advanced disease. You must be an adult woman with LAM to participate. It is not a requirement that you are already taking one of these medicines. If you are not taking one of these medicines and previously did not respond to or could not tolerate one of these medicines, you may still be able to participate in this study. Visit Safety and Durability of Sirolimus for Treatment of LAM (MIDAS) for more information and to learn how to participate in this study.

Are you an adult woman with LAM who wants to support future studies of a new treatment?

This study is examining whether saracatinib is safe and improves lung function in people who have LAM. Saracatinib inhibits Src kinase, a protein that is known to have increased activity in TSC mutant cells. You must be a woman with LAM between the ages of 18 and 65 to participate. Visit Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis (SLAM-2) for more information and to learn how to participate in this study.

Are you an adult woman with LAM who wants to support future studies of a new treatment or biomarker of disease severity?

This study is examining whether celecoxib is a safe and well tolerated in people who have LAM. Celecoxib inhibits COX-2, a protein known to have increased activity in TSC mutant cells. This study can help researchers optimize future studies aimed at determining how effective celecoxib is at shrinking growths of TSC mutant cells, improving lung function, and being a long-term treatment option for patients with LAM. This study is also exploring whether the amount of TSC-mutant LAM cells in the blood is a biomarker for disease severity. You must be a woman with LAM between the ages of 18 and 70 to participate. Visit COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC (COLA) for more information and to learn how to participate in this study.

Are you an adult woman with LAM who wants to try albuterol to improve lung function?

This study is examining which delivery method of albuterol—inhaled or nebulizer—is better at improving lung function in adult women with LAM. Visit Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis for more information and to learn how to participate in this study.